Semax Selank peptide

The Selank peptide is most commonly administered intranasally in published research, though subcutaneous injection protocols also exist. The intranasal route provides direct access to the CNS via the olfactory epithelium, bypassing the blood-brain barrier — which is why nasal administration is preferred for cognitive and anxiolytic research with this compound. Reconstitution: Lyophilized Selank peptide is typically reconstituted in bacteriostatic water for subcutaneous applications or pharmaceutical-grade saline for intranasal preparations. Standard reconstitution involves adding solvent slowly to the peptide vial while gently swirling — never vortexing, which can disrupt peptide structure and reduce bioactivity. Researchers should allow the solution to equilibrate at room temperature for five to ten minutes before use. Storage: Lyophilized powder should be stored at -20°C for long-term preservation (up to 24 months under optimal conditions). Reconstituted Selank solution is stable for up to 28 days at 2–8°C with bacteriostatic water. Avoid repeated freeze-thaw cycles, which degrade peptide integrity and reduce biological activity. For complete storage protocols applicable to all research peptides, see the peptide storage guide. Dosing in published research: Intranasal protocols in published clinical research typically use 250–500 mcg per administration, two to three times daily over cycles of one to four weeks. Subcutaneous protocols in animal research use weight-adjusted doses. Researchers should consult the peptide dosage calculator guide for accurate preparation calculations and unit conversion formulas. Purity verification: Researchers should verify Selank identity and purity through HPLC and mass spectrometry analysis via Certificate of Analysis (COA). A minimum purity of 98%+ is recommended for research-grade material. A reputable research chemical supplier will provide third-party analytical testing with each batch. For guidance on interpreting analytical certificates, see the peptide purity and COA guide. Full reconstitution walkthrough: For a step-by-step guide to peptide preparation, the how to reconstitute peptides guide covers the complete process from lyophilized powder to injection-ready solution, including volumes, ratios, and sterile technique.

Selank Research: What the Studies Actually Show Selank is a synthetic analog of the immunopeptide tuftsin, studied mainly in rodent behavioral and gene-expression models. What the peer-reviewed research reports — and what stays preclinical. Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use. Selank, like semax, is a Russian-developed research peptide with a literature concentrated on the central nervous system. This summary surveys what the peer-reviewed studies report and where the evidence stands. For the format used across this series, see our BPC-157 research review. What selank is Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide, with sequence modifications for stability. It is studied for central-nervous-system and immune-related effects. What the research reports Rodent behavioral studies examine selank in anxiety and stress models: a 2017 study reported it enhanced the anxiety-reducing effect of diazepam in a chronic-mild-stress rat model, and a 2019 study reported effects on BDNF content in the hippocampus and prefrontal cortex in a rat memory model. At the molecular level, a 2016 Frontiers in Pharmacology study reported effects on genes involved in GABAergic neurotransmission, and a 2018 review summarized the molecular aspects of its biological activity. These are behavioral and gene-expression findings in rats. The human-evidence gap As with semax, selank is used clinically in Russia but is not FDA-approved, and the independent international literature is dominated by rodent studies. Large, controlled human trials are limited. The takeaway Selank has a consistent rodent behavioral and gene-expression literature centered on stress, anxiety, and GABAergic and neurotrophic signaling. The human evidence, internationally, remains thin. Frequently Asked Questions What is selank derived from? The natural immunopeptide tuftsin, modified for stability; it is studied for central-nervous-system and immune-related effects. What models is selank studied in? Primarily rat behavioral models of anxiety and stress, plus gene-expression studies of pathways such as GABAergic neurotransmission. Is selank approved by the FDA? No. It is used clinically in Russia but is not FDA-approved. American Peptides supplies it strictly for in vitro research. Does selank affect BDNF in studies? A 2019 rat study reported effects on BDNF content in the hippocampus and prefrontal cortex; the findings are preclinical. Citations “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behav Neurol. 2017. PubMed: PMID 28280289 “Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.” Bull Exp Biol Med. 2019. PubMed: PMID 31625062 Kolomin T, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Front Pharmacol. 2016. PubMed: PMID 26924987 “Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.” Protein Pept Lett. 2018. PubMed: PMID 30255741